NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: WANBURY · data 2026-11-01
Wanbury Limited
In plain words
Price: 47.3% below its 52-week high of ₹358.85.
Delivery: 45.1% of traded shares were kept for delivery over the last 10 sessions, against 46.9% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Jun 2026 (-76.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹653 cr |
| Net profit (last 12 months) | ₹56 cr |
| Sales growth, 3 years (yearly) | 8.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 43.0% (-0.1 pts in a year), pledged 5.5%, institutions 0.7%.
P/E 11.6, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 64.9%, ROCE 31.1%, operating margin 12.8%: how much profit it earns on the money it uses.
Debt/equity 1.57, Profit growth — and sales growth 8.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (64.9%).
- High borrowing: debt/equity 1.57.
- Promoters have pledged 5.5% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
WANBURY Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹165.58 crore, up 1.5% YoY and up 0.6% QoQ.
Net profit was ₹3.24 crore, down 76% YoY and down 85.1% QoQ.
Operating margin was 9.8% (15% a year ago).
EPS was ₹0.93, down 77.4% YoY and down 85.1% QoQ.
WANBURY के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹165.58 करोड़; पिछले साल की तुलना में 1.5% की बढ़त, पिछली तिमाही की तुलना में 0.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹3.24 करोड़; पिछले साल की तुलना में 76% की गिरावट, पिछली तिमाही की तुलना में 85.1% की गिरावट।
ऑपरेटिंग मार्जिन: 9.8% (एक साल पहले 15%)।
EPS: ₹0.93; पिछले साल की तुलना में 77.4% की गिरावट, पिछली तिमाही की तुलना में 85.1% की गिरावट।
WANBURYના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹165.58 કરોડ; ગયા વર્ષની સરખામણીએ 1.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 0.6% વધારો.
ચોખ્ખો નફો: ₹3.24 કરોડ; ગયા વર્ષની સરખામણીએ 76% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 85.1% ઘટાડો.
ઓપરેટિંગ માર્જિન: 9.8% (એક વર્ષ પહેલાં 15%).
EPS: ₹0.93; ગયા વર્ષની સરખામણીએ 77.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 85.1% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 46.3% over the last 20 sessions vs 43.9% in the 40 before (1.05x); shares delivered per day 1.04x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹3.94 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 6 Oct 26Deal Bulk deal: DHUNSERI VENTURES LIMITED sold ₹3.94 cr +4.3% next session
- 11 Aug 26Results Q1 FY27 results: profit −76.0% YoY +6.7% next session
- 29 May 26Results Q4 FY26 results: profit +7.1% YoY -11.2% next session
- 5 Feb 26Results Q3 FY26 results: profit +1191.8% YoY -5.1% next session
- 13 Nov 25Results Q2 FY26 results: profit +89.3% YoY -1.1% next session
- 4 Aug 25Results Q1 FY26 results: profit +1197.1% YoY -1.0% next session
- 15 May 25Results Q4 FY25 results: profit +150.7% YoY +12.9% next session
- 12 Feb 25Results Q3 FY25 results: profit −88.1% YoY +6.1% next session
- 14 Nov 24Results Q2 FY25 results: profit +9.0% YoY -8.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹166 cr | ₹3 cr | -76.0% | 9.8% | 0.93 |
| Mar 2026 | ₹165 cr | ₹22 cr | +7.1% | 18.1% | 7.33 |
| Dec 2025 | ₹162 cr | ₹16 cr | +1191.8% | 16.4% | 4.52 |
| Sept 2025 | ₹160 cr | ₹15 cr | +89.3% | 16.1% | 4.58 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 42.98% | 43.02% | 43.02% | 43.07% |
| Foreign institutions (FII) | 0.71% | 0.89% | 0.59% | 0.72% |
| Domestic institutions (DII) | 0.02% | 0.06% | 0.00% | 0.00% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 23.84% | 20.76% | 20.58% | 21.33% |
| Number of shareholders | 20,432 | 17,174 | 16,732 | 17,261 |
Common questions
What was Wanbury Limited's latest quarterly profit?
Wanbury Limited reported a net profit of ₹3 cr for the quarter ended Jun 2026 (-76.0% on the same quarter a year earlier), on revenue of ₹166 cr.
How much do promoters hold in Wanbury Limited?
Promoters held 42.98% of Wanbury Limited at the end of Sept 2026, with 5.49% of promoter shares pledged.
Is Wanbury Limited debt-free?
Its latest reported debt-to-equity ratio is 1.57, meaning borrowings are larger than shareholders' equity.
What is Wanbury Limited's P/E ratio?
About 11.6, based on the last 12 months' earnings and a price of ₹189.21 (data 2026-11-01).
What is the 52-week high and low of Wanbury Limited?
The 52-week high is ₹358.85 and the 52-week low is ₹161.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Wanbury Limited | ₹189.21 | ₹664 cr | 11.6 | — | 64.9% | 31.1% | 1.57 | -25.8% |
| Shree Ganesh Remedies Ltd. | ₹617.25 | ₹792 cr | 51.3 | — | 11.5% | 14.4% | 0.19 | +24.7% |
| Kilitch Drugs (India) Limited | ₹201.32 | ₹703 cr | 23 | — | 12.5% | 12.3% | 0.32 | +1.5% |
| Valiant Laboratories Ltd. | ₹128.4 | ₹695 cr | 43.5 | — | -1.2% | 0.2% | 0.15 | +48.6% |
| Hexagon Nutrition Limited | ₹54.11 | ₹664 cr | — | — | 17.7% | 18.7% | 0.14 | +12.1% |
| Amanta Healthcare Limited | ₹163.56 | ₹632 cr | 43.3 | — | 9.4% | 11.5% | 1.11 | +33.5% |
Compare WANBURY with SGRL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open WANBURY in NSE Scanner →